|
| Variable | Results | value, females vs. males |
| All | Females | Males |
|
| Gender | 581 | 309 (53.2%) | 272 (46.8%) | n.a. |
| Age (years±SD) | 81.2±10.1 | 82.3±0.6 | 80±0.5 | 0.006 |
| In-hospital stay (days±SD) | 13.1±10.8 | 12.6±0.6 | 13.5±0.6 | 0.31 |
| CKD stage (% of all individuals) | Females: II—1.9, IIIa—14.3, IIIb—36.4, IV—37.1, V—9.2 | n.a. |
| Males: II—2.9, IIIa—12.7, IIIb—35.1, IV—39.6, V—10.2 |
| CKD diagnosis documented (%) | 90.0 | 89.3 | 92.6 | 0.16 |
| CKD etiology documented (%) | 82.1 | 79.9 | 84.6 | 0.14 |
| Diagnosis of hypertension documented (%) | 59.2 | 57.9 | 60.7 | 0.5 |
| RAS inhibitor at the time of discharge (no+/−ACE inhibitor—sartan in %) | No | 26.5 | 26.5 | 26.5 | 0.72 |
| ACE i | 38.9 | 37.5 | 40.4 |
| sartan | 34.6 | 35.9 | 33.1 |
| Quantification of serum phosphate (%) | 12.9 | 13.9 | 11.8 | 0.4 |
| Quantification of PTH (%) | 5.5 | 5.8 | 5.1 | 0.72 |
| Quantification of 25-OH-D3 (%) | 6 | 6.8 | 5.1 | 0.4 |
| Phosphate binder recommended (%) | 3.6 | 4.5 | 2.6 | 0.2 |
| Vitamin D recommended (%) | 23.1 | 27.5 | 18 | 0.007 |
| Diagnosis of CKD-MBD documented (%) | 0.3 | 0.3 | 0.4 | 0.92 |
| Quantification of ferritin (%) | 14.6 | 13.3 | 16.2 | 0.32 |
| Quantification of transferrin saturation (%) | 13.6 | 12.9 | 14.3 | 0.62 |
| Iron therapy recommended if necessary (%) | 12.7 | 10 | 15.8 | 0.03 |
| Erythropoietin therapy recommended if necessary (%) | 1 | 0.6 | 1.5 | 0.32 |
| Diagnosis of renal anemia documented (%) | 3.8 | 3.9 | 3.7 | 0.89 |
| Assessment of proteinuria (%) | 10.3 | 10.4 | 10.3 | 0.98 |
| Blood gas analysis performed (%) | 55.1 | 53.4 | 57 | 0.38 |
| Bicarbonate therapy recommended (%) | 5 | 4.8 | 4 | 0.32 |
| Nephrology follow-up recommended (%) | 27 | 25.6 | 28.7 | 0.4 |
|
